Alex Schwartz

vTv Therapeutics Inc (NASDAQ: VTVT) announced Monday after the close that results from Part A of its late-stage study of an investigational medication to treat Alzheimer's disease did not meet either co-primary endpoint. Patients taking its pipeline candidate azeliragon, when compared with a...

The Street has long been ambivalent on Momenta Pharmaceuticals, Inc. (NASDAQ: MNTA)'s prospects. But the generic drug developer scored one new advocate Thursday on the basis of its pipeline potential. The Rating Stifel Nicolaus analyst Alex Schwartz upgraded Momenta from Hold to Buy and...